Eisai appoints president of US operations

Share this article:
Eisai president Cynthia Schwalm
Eisai president Cynthia Schwalm

Eisai announced the immediate appointment of Cynthia Schwalm as president of Eisai Inc., a US-based commercial, marketing and sales operation, effective May 5. 

Schwalm will report to Lonnel Coats, president and COO of Eisai Corporation of North America, an umbrella entity that supports the company's various commercial operations in the US, including Eisai Inc. 

“Ms. Schwalm is an exciting addition to our company. She will be instrumental in driving Eisai's integration of MGI PHARMA and strengthening our presence in the US as a top-20 pharmaceutical company,” said Coats in a statement. Eisai completed the acquisition of MGI PHARMA – for $3.9 billion – in January 2008.

Schwalm was previously vice president and general manager of US Oncology Business Unit, at Amgen, Inc.  Before that she worked at various Johnson & Johnson companies, most recently as managing director of Ortho Biotech's offices in the UK and Ireland.

Coats was previously the president and COO at both Eisai Inc. and Eisai Corporation of North America.  With Schwalm as president, Eisai Inc. will no longer have a COO. Coats will retain duties as president and COO at Eisai Corporation of North America.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...